105 related articles for article (PubMed ID: 12429526)
41. Hydrophobic mutations in buried polar residues enhance HIV-1 gp41 N-terminal heptad repeat-C-terminal heptad repeat interactions and C-peptides' anti-HIV activity.
Zheng B; Wang K; Lu L; Yu F; Cheng M; Jiang S; Liu K; Cai L
AIDS; 2014 Jun; 28(9):1251-60. PubMed ID: 24625369
[TBL] [Abstract][Full Text] [Related]
42. Heteromeric assembled polypeptidic artificial hydrolases with a six-helical bundle scaffold.
Bai Y; Ling Y; Shi W; Cai L; Jia Q; Jiang S; Liu K
Chembiochem; 2011 Nov; 12(17):2647-58. PubMed ID: 21957084
[TBL] [Abstract][Full Text] [Related]
43. Role of the fusion peptide and membrane-proximal domain in HIV-1 envelope glycoprotein-mediated membrane fusion.
Dimitrov AS; Rawat SS; Jiang S; Blumenthal R
Biochemistry; 2003 Dec; 42(48):14150-8. PubMed ID: 14640682
[TBL] [Abstract][Full Text] [Related]
44. Rapid and automated fluorescence-linked immunosorbent assay for high-throughput screening of HIV-1 fusion inhibitors targeting gp41.
Liu S; Boyer-Chatenet L; Lu H; Jiang S
J Biomol Screen; 2003 Dec; 8(6):685-93. PubMed ID: 14711394
[TBL] [Abstract][Full Text] [Related]
45. Investigation of the inhibition effect of arachidonic acid on the core structure of the HIV-1 gp41.
Xu X; Li L; Liu Z; Yao X; Zhang X; Liu S; Liu L
J Pharm Biomed Anal; 2018 Nov; 161():377-382. PubMed ID: 30199809
[TBL] [Abstract][Full Text] [Related]
46. Creating an Artificial Tail Anchor as a Novel Strategy To Enhance the Potency of Peptide-Based HIV Fusion Inhibitors.
Su S; Zhu Y; Ye S; Qi Q; Xia S; Ma Z; Yu F; Wang Q; Zhang R; Jiang S; Lu L
J Virol; 2017 Jan; 91(1):. PubMed ID: 27795416
[TBL] [Abstract][Full Text] [Related]
47. Six-helix bundle completion in the distal C-terminal heptad repeat region of gp41 is required for efficient human immunodeficiency virus type 1 infection.
Liu D; Wang H; Yamamoto M; Song J; Zhang R; Du Q; Kawaguchi Y; Inoue JI; Matsuda Z
Retrovirology; 2018 Apr; 15(1):27. PubMed ID: 29609648
[TBL] [Abstract][Full Text] [Related]
48. The HIV gp41 pocket binding domain enables C-terminal heptad repeat transition from mediating membrane fusion to immune modulation.
Klug YA; Kapach G; Rotem E; Dubreuil B; Shai Y
Biochem J; 2016 Apr; 473(7):911-8. PubMed ID: 26823547
[TBL] [Abstract][Full Text] [Related]
49. A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure.
Binley JM; Sanders RW; Clas B; Schuelke N; Master A; Guo Y; Kajumo F; Anselma DJ; Maddon PJ; Olson WC; Moore JP
J Virol; 2000 Jan; 74(2):627-43. PubMed ID: 10623724
[TBL] [Abstract][Full Text] [Related]
50. Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target.
Chan DC; Chutkowski CT; Kim PS
Proc Natl Acad Sci U S A; 1998 Dec; 95(26):15613-7. PubMed ID: 9861018
[TBL] [Abstract][Full Text] [Related]
51. Core structure of gp41 from the HIV envelope glycoprotein.
Chan DC; Fass D; Berger JM; Kim PS
Cell; 1997 Apr; 89(2):263-73. PubMed ID: 9108481
[TBL] [Abstract][Full Text] [Related]
52. Novel recombinant engineered gp41 N-terminal heptad repeat trimers and their potential as anti-HIV-1 therapeutics or microbicides.
Chen X; Lu L; Qi Z; Lu H; Wang J; Yu X; Chen Y; Jiang S
J Biol Chem; 2010 Aug; 285(33):25506-15. PubMed ID: 20538590
[TBL] [Abstract][Full Text] [Related]
53. Dissection of human immunodeficiency virus type 1 entry with neutralizing antibodies to gp41 fusion intermediates.
Golding H; Zaitseva M; de Rosny E; King LR; Manischewitz J; Sidorov I; Gorny MK; Zolla-Pazner S; Dimitrov DS; Weiss CD
J Virol; 2002 Jul; 76(13):6780-90. PubMed ID: 12050391
[TBL] [Abstract][Full Text] [Related]
54. Covalent stabilization of coiled coils of the HIV gp41 N region yields extremely potent and broad inhibitors of viral infection.
Bianchi E; Finotto M; Ingallinella P; Hrin R; Carella AV; Hou XS; Schleif WA; Miller MD; Geleziunas R; Pessi A
Proc Natl Acad Sci U S A; 2005 Sep; 102(36):12903-8. PubMed ID: 16129831
[TBL] [Abstract][Full Text] [Related]
55. HIV-1 gp41 Residues Modulate CD4-Induced Conformational Changes in the Envelope Glycoprotein and Evolution of a Relaxed Conformation of gp120.
Keller PW; Morrison O; Vassell R; Weiss CD
J Virol; 2018 Aug; 92(16):. PubMed ID: 29875245
[TBL] [Abstract][Full Text] [Related]
56. Membrane-anchored inhibitory peptides capture human immunodeficiency virus type 1 gp41 conformations that engage the target membrane prior to fusion.
Melikyan GB; Egelhofer M; von Laer D
J Virol; 2006 Apr; 80(7):3249-58. PubMed ID: 16537592
[TBL] [Abstract][Full Text] [Related]
57. Antiviral properties of two trimeric recombinant gp41 proteins.
Delcroix-Genête D; Quan PL; Roger MG; Hazan U; Nisole S; Rousseau C
Retrovirology; 2006 Mar; 3():16. PubMed ID: 16515685
[TBL] [Abstract][Full Text] [Related]
58. Preparation and characterization of four novel monoclonal antibodies specific to N51(L6)C46 polypeptide simulating fusogenic core structure of GP41 subunit of HIV-1.
Chen Z; Hong L; Li Z; Fan D; Huang Q; Wang H; Li Z; Xu Z
Hybridoma (Larchmt); 2006 Oct; 25(5):278-82. PubMed ID: 17044783
[TBL] [Abstract][Full Text] [Related]
59. Evaluation of the contribution of the transmembrane region to the ectodomain conformation of the human immunodeficiency virus (HIV-1) envelope glycoprotein.
Nguyen HT; Madani N; Ding H; Elder E; Princiotto A; Gu C; Darby P; Alin J; Herschhorn A; Kappes JC; Mao Y; Sodroski JG
Virol J; 2017 Feb; 14(1):33. PubMed ID: 28209172
[TBL] [Abstract][Full Text] [Related]
60. Efficient Fusion at Neutral pH by Human Immunodeficiency Virus gp41 Trimers Containing the Fusion Peptide and Transmembrane Domains.
Liang S; Ratnayake PU; Keinath C; Jia L; Wolfe R; Ranaweera A; Weliky DP
Biochemistry; 2018 Feb; 57(7):1219-1235. PubMed ID: 29345922
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
